20386-22-5

Basic information

• Product Name: 1-aminopyrrolidin-2-one hydrochloride
• Synonyms: 2-Pyrrolidinone, 1-aMino-, hydrochloride;1-aMinopyrrolidin-2-one.HCl;1-Aminopyrrolidinone hydrochloride;1-amino-2-Pyrrolidinone hydrochloride (1:1);1-aminopyrrolidin-2-one hydrochloride;2-Pyrrolidinone, 1-aMino-, hydrochloride (1:1)
• CAS NO: 20386-22-5
• Molecular Formula: C₄H₈N₂O*ClH
• Molecular Weight: 136.58
• Mol File: 20386-22-5.mol
• Article Data: 3

Chemical Properties

• Melting Point: 227 °C at 760 mmHg
• Boiling Point: 91.1 °C
• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Solubility: DMSO (Slightly), Methanol (Slightly), Water (Slightly)
• CAS DataBase Reference: 1-aminopyrrolidin-2-one hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 1-aminopyrrolidin-2-one hydrochloride(20386-22-5)
• EPA Substance Registry System: 1-aminopyrrolidin-2-one hydrochloride(20386-22-5)

Safety Data

• Hazardous Substances Data: 20386-22-5(Hazardous Substances Data)

Usage

Uses

1-Aminopyrrolidin-2-one Hydrochloride is used for the optimization of dihydropyrrolopyrazole series for transforming the growth factor-β type I receptor kinase domain inhibitor and also for the discovery of an orally bioavailable antitumor agent.

Upstream product

• 79289-48-8 1-<(diphenylmethylene)amino>pyrrolidin-2-one 

Downstream Products

• 1264670-28-1 1-(2-phenyl-indol-1-yl)pyrrolidin-2-one 
• 660432-30-4 3-ethoxycarbonyl-2-phenyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole 

Relevant articles and documents

POLYAROMATIC UREA DERIVATIVES AND THEIR USE IN THE TREATMENT OF MUSCLE DISEASES

The current invention provides urea derivatives, in particular compounds having the core structure heteroaryl-NH-CO-NH-aryl-O- heteroaryl, for use in treating, ameliorating, delaying, curing and/ or preventing a disease or condition associated with muscle cells and/or satellite cells, such as Duchenne muscular dystrophy, Becker muscular dystrophy, cachexia or sarcopenia.

MIXED LINEAGE KINASE MODULATORS

The present invention provides a compound of the formula: (Formula I); or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising an effective amount of a compound of Formula I in combination with a suitable carrier, diluent, or excipient, and methods for treating physiological disorders, particularly congestive heart disease, comprising administering to a patient in thereof an effective amount of a compound of Formula I.